Sentinel Initiative

Sentinel Initiative is a set of efforts by U.S. Food and Drug Administration (FDA) that tries to improve the ability to identify and evaluate safety of medicinal products.[1][2]

It has several parts: Sentinel System,[3] Postmarket Rapid Immunization Safety Monitoring (PRISM) system, and Blood Safety Continuous Active Surveillance Network (BloodSCAN).[4] Part of Sentinel Initiative is a surveillance program for biologics. It is called Biologics Effectiveness and Safety (BEST) Initiative.[5]

Sentinel System

The Sentinel System uses pre-existing electronic healthcare data (including billing data). Part of the Sentinel System is a tool called Active Postmarket Risk Identification and Analysis (ARIA) system that was mandated in the U.S. Food and Drug Administration (FDA) Amendments Act (FDAAA) of 2007.[6]

See also

References
  1. "Sentinel Initiative Website".
  2. Racoosin, Judith A.; Robb, Melissa A.; Sherman, Rachel E.; Woodcock, Janet (2012-01-03). "Chapter 30: FDA's Sentinel Initiative: Active Surveillance to Identify Safety Signals". In Strom, Brian L.; Kimmel, Stephen E.; Hennessy, Sean (eds.). Pharmacoepidemiology. Wiley-Blackwell. pp. 534–554. doi:10.1002/9781119959946.ch30. ISBN 9781119959946.
  3. Ball, R; Robb, M; Anderson, SA; Dal Pan, G (2016). "The FDA's sentinel initiative--A comprehensive approach to medical product surveillance". Clin Pharmacol Ther. 99 (3): 265–8. doi:10.1002/cpt.320. PMID 26667601.
  4. "Sentinel Description". FDA.
  5. "The Biologics Effectiveness and Safety Initiative". BEST Initiative.
  6. "Background". FDA.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.